Immunovant Inc [IMVT] stock is trading at $24.3, up 2.36%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IMVT shares have gain 3.98% over the last week, with a monthly amount glided 38.78%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunovant Inc [NASDAQ: IMVT] stock has seen the most recent analyst activity on October 14, 2025, when Truist initiated its Hold rating and assigned the stock a price target of $16. On March 03, 2025, Jefferies initiated with a Hold rating and assigned a price target of $20 on the stock. Wolfe Research downgraded its rating to a Peer Perform. Oppenheimer reiterated an Outperform rating for this stock on October 09, 2024, and upped its price target to $53. In a note dated March 28, 2024, Oppenheimer initiated an Outperform rating and provided a target price of $50 on this stock.
Immunovant Inc [IMVT] stock has fluctuated between $12.72 and $29.49 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $24.3 at the most recent close of the market. An investor can expect a potential drop of -34.16% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.8, Equity is -0.85 and Total Capital is -0.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.62 points at the first support level, and at 22.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.85, and for the 2nd resistance point, it is at 25.41.
Ratios To Look Out For
For context, Immunovant Inc’s Current Ratio is 9.07. In addition, the Quick Ratio stands at 9.07 and the Cash Ratio stands at 8.25.
Transactions by insiders
Recent insider trading involved Geffner Michael, Chief Medical Officer, that happened on Oct 22 ’25 when 2595.0 shares were sold. Chief Technology Officer, Stout Jay S completed a deal on Oct 22 ’25 to sell 2520.0 shares. Meanwhile, Chief Medical Officer Geffner Michael sold 1272.0 shares on Oct 08 ’25.
